However, because Adavivint can inhibit several other kinases and CLK is actively involved in pre-mRNA processing, we cannot rule out the impact on other signaling pathways that could explain the overall anti-tumor mechanism of this drug. This evidence concerns the gene CLK1 and neoplasm.